Real-world data/evidence case studies

Symphony Health partnered with a social media company to develop a privacy-compliant ad measurement solution for a pharma client. Using machine learning, they maintained 90% accuracy while meeting stricter privacy standards—offering a scalable model for regulated environments.

Understanding Social Determinants of Health (SDOH) is key to addressing disparities and improving outcomes in Type 2 Diabetes. While factors like diet and access to care are known, quantifying their impact on diagnosis, treatment initiation, and adherence remains an emerging focus.

A pharma company partnered with Symphony Health to guide the launch of a TYK2 inhibitor for psoriasis. They explored market potential, free drug programs, treatment patterns, and prescribing behavior—especially among NPs and PAs—to shape positioning in a competitive landscape.

CGRP inhibitors have expanded migraine treatment, but payer barriers often limit access, especially for vulnerable groups. A patient advocacy client worked with Symphony Health to explore disparities in access and their impact on outcomes like ER visits and hospitalizations.

Early cancer detection is vital, yet many cases—especially lung cancer—are diagnosed late, limiting treatment options. Life sciences organizations now use real-world data and machine learning to identify subtle, pre-diagnostic signals in patient journeys, enabling earlier intervention and improved outcomes.

Pulmonary arterial hypertension (PAH) often presents with vague symptoms, making diagnosis difficult and leading to frequent delays or misdiagnoses. While current treatments have improved outcomes, underserved populations with limited access to specialized care remain under treated.

Symphony Health, an ICON plc company, and a trusted provider of healthcare data and analytics, collaborated with
Butler/Till to enhance the digital media buying strategy for a major pharmaceutical company.

A major pharmaceutical client explored whether a wellness app for glucose monitoring and nutrition coaching could reduce A1c levels in Type 2 Diabetes patients. They also assessed its potential to lower healthcare costs and its commercial viability for payer-supported integration into treatment plans.

In Q1 2024, Underscore Marketing launched an innovative unbranded campaign to educate patients with a rare lung disease. Using advanced data and privacy-compliant methods, the initiative validated symptoms and introduced a soon-to-be FDA-approved treatment, setting a new benchmark for disease education in healthcare.

As a part of their ongoing Test & Learn strategy, dentsu health collaborated with several data partners to assess healthcare claims models and measure Audience Quality across two direct-to-consumer (DTC) display campaigns.